- Home
- POWW vs NGEN Comparison
POWW vs NGEN Comparison
Compare POWW & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | POWW | NGEN |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.6M | 200.0M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | POWW | NGEN |
|---|---|---|
| Price | $2.17 | $2.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.40 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 604.4K | 512.5K |
| Earning Date | 02-09-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.61 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.56 | N/A |
| Revenue Next Year | $0.50 | N/A |
| P/E Ratio | $108.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.39 | $1.58 |
| 52 Week High | $2.67 | $5.93 |
Technical Indicators
Market Signals| Indicator | POWW | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 70.70 |
| Support Level | $1.94 | $1.62 |
| Resistance Level | $2.23 | $2.28 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 10.20 | 78.57 |
Price Performance
Historical ComparisonAbout POWW AMMO Inc.
Outdoor Holding Co the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketplace segment consists of the GunBroker e-commerce marketplace. The company generates the majority of its revenue from the Ammunition segment.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.